NDT Advance Access originally published online on July 28, 2006
Nephrology Dialysis Transplantation 2006 21(11):3243-3251; doi:10.1093/ndt/gfl397
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of ciclosporin A to tacrolimus in kidney transplant recipients with chronic allograft nephropathy

Division of Nephrology, Department of Medicine, University of Hong Kong and Queen Mary Hospital, Hong Kong, China
Correspondence and offprint requests to: Prof. T. M. Chan, Department of Medicine, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong SAR, China. Email: dtmchan{at}hku.hk
Background. Tacrolimus and ciclosporin might have different effects on intra-renal fibrosis and allograft function in chronic allograft nephropathy (CAN). It is difficult to predict the response to calcineurin inhibitor minimization in patients with CAN.
Methods. This prospective randomized study compared ciclosporin A (CsA)-to-tacrolimus conversion (group A, target tacrolimus trough level 68 ng/ml) vs CsA minimization (group B, target CsA trough level 80100 ng/ml) with regard to efficacy and safety in patients with CAN and deteriorating allograft function. The primary efficacy endpoint was improvement in the slope of inverse serum creatinine (1/SCr) vs time plot.
Results. There were 34 evaluable patients (n = 16 in group A; n = 18 in group B), with similar baseline characteristics. Both groups reached target drug levels after a 3-month run-in period. Over the ensuing 12 months, nine (56.3%) subjects in group A and 10 (55.6%) in group B reached the primary end point (P = 0.968). Both groups showed considerable improvement in the slope of 1/SCr vs time plot. There was no significant difference in the slope between groups before and after intervention. Graft survival was 87% in group A and 100% in group B (P = 0.121). Acute rejection was encountered in two group A subjects. There was no significant change or difference in blood glucose, lipids, and blood pressure between groups.
Conclusion. Our results suggest that in patients with CAN and deteriorating allograft function, CsA-to-tacrolimus conversion or CsA minimization achieved comparable efficacies in retarding the decline of graft function. Such contention may be biased by the low patient number. Further studies with a larger cohort are needed for validation.
Keywords: chronic allograft nephropathy; ciclosporin A; minimization; tacrolimus conversion
Please refer to Appendix for participants in the Study Group.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
L. M. Birnbaum, M. Lipman, S. Paraskevas, P. Chaudhury, J. Tchervenkov, D. Baran, A. Herrera-Gayol, and M. Cantarovich Management of Chronic Allograft Nephropathy: A Systematic Review Clin. J. Am. Soc. Nephrol., April 1, 2009; 4(4): 860 - 865. [Abstract] [Full Text] [PDF] |
||||
